<DOC>
	<DOCNO>NCT03014895</DOCNO>
	<brief_summary>The study ( E3112/CP1 ) single-center , randomize , double-blind , placebo-controlled , single intravenous ascend dose study conduct Japanese healthy adult male evaluate pharmacokinetics ( PK ) , safety , immunogenicity E3112 follow single intravenous dose E3112 .</brief_summary>
	<brief_title>A Single Intravenous Dose Study E3112 Japanese Healthy Adult Male Subjects</brief_title>
	<detailed_description />
	<criteria>Main Nonsmoking , Japanese , male participant , ≥20 &lt; 45 year old time obtain inform consent Have Body Mass Index ( BMI ) ≥18.5 &lt; 25.0 kilogram per meter square ( kg/m^2 ) Screening Able provide write informed consent free Males give full explanation requirement protocol , willing able comply Main Male partner agree use highly effective method contraception throughout entire study period , reproductive capacity Male malignant tumor , lymphoma , leukaemia , lymphoproliferative disorder . Clinically significant illness require medical treatment within 8 week clinically significant infection within 4 week prior dose . Evidence disease may influence outcome study within 4 week prior dose Any history surgical treatment may affect pharmacokinetic ( PK ) profile study drug Screening Any suspect clinically abnormal symptom organ impairment require medical treatment Screening Baseline Receipt vaccination within 4 week prior dose History drug alcohol dependency abuse prior Screening Intake caffeinated beverage food within 72 hour prior dose Use prescription drug within 4 week prior dose Intake overthecounter ( OTC ) medication within 2 week prior dose Male currently enrol another clinical study use investigational drug device another clinical study within 16 week prior dose Male underwent blood transfusion within 12 week prior dose , donate 400 milliliter ( mL ) whole blood within 12 week prior dose , donate 200 mL whole blood within 4 week prior dose , make component donation within 2 week prior dose</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>E3112</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japanese</keyword>
</DOC>